Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Loncastuximab tesirine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Loncastuximab tesirine||Lonca||ADCT-402||CD19 Antibody 9||Loncastuximab tesirine (ADCT-402) is a human anti-CD19 antibody in conjugation with a pyrrolobenzodiazepine (PBD) dimer toxin, which may specifically target CD19-positive tumor cells (Blood 2017 130(Suppl 1):187, PMID: 32012214).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||B-cell acute lymphoblastic leukemia||not applicable||Loncastuximab tesirine||Phase I||Actionable||In a Phase I trial, Loncastuximab tesirine (ADCT-402) treatment demonstrated manageable safety profile, resulted in a complete response in 8.5% (3/35) of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (PMID: 32012214; NCT02669264).||32012214|
|Unknown unknown||diffuse large B-cell lymphoma||not applicable||Loncastuximab tesirine||Phase I||Actionable||In a Phase I trial, Loncastuximab tesirine treatment resulted in an objective response rate of 57.1% (20/35) with a complete response rate of 34.3% (12/35) in patients with diffuse large B-cell lymphoma (Blood 2017 130(Suppl 1):187, NCT02669017).||detail...|
|Unknown unknown||B-cell lymphoma||not applicable||Loncastuximab tesirine||Phase I||Actionable||In a Phase I trial, Loncastuximab tesirine treatment demonstrated safety and preliminary efficacy, resulted in an overall response rate of 59.4% (41/69, 28 complete response, 13 partial response) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, with median duration of response, progression-free survival, and overall survival of 4.8, 5.5, and 11.6 months, respectively (PMID: 31685491; NCT02669017).||31685491|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03589469||Phase II||Loncastuximab tesirine||Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma||Active, not recruiting|